[MRDIY] QoQ TTM Result on 31-Dec-2022 [#4]

Stock
[MRDIY] MR D.I.Y. GROUP (M) BERHAD
Announcement Date
14-Feb-2023
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2022
Quarter
31-Dec-2022 [#4]
Profit Trend
QoQ- 0.32%
YoY- 9.52%
Quarter Report
Latest QR
Upcoming QR
MRDIY's Result
MRDIY's Financial Summary
View:
Show?
TTM Result
30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 CAGR
Revenue 4,278,351 4,177,984 4,127,080 3,985,842 3,895,450 3,697,306 3,408,390 16.34%
PBT 729,889 697,397 679,409 641,365 631,529 620,990 550,248 20.70%
Tax -191,771 -182,042 -179,191 -168,416 -160,105 -160,399 -142,710 21.75%
NP 538,118 515,355 500,218 472,949 471,424 460,591 407,538 20.33%
-
NP to SH 538,118 515,355 500,218 472,949 471,424 460,591 407,538 20.33%
-
Tax Rate 26.27% 26.10% 26.37% 26.26% 25.35% 25.83% 25.94% -
Total Cost 3,740,233 3,662,629 3,626,862 3,512,893 3,424,026 3,236,715 3,000,852 15.80%
-
Net Worth 1,657,187 1,602,726 1,507,246 1,432,208 1,338,592 1,292,258 1,254,479 20.37%
Dividend
30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 CAGR
Div 264,129 235,764 216,851 204,232 204,164 197,828 178,934 29.61%
Div Payout % 49.08% 45.75% 43.35% 43.18% 43.31% 42.95% 43.91% -
Equity
30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 CAGR
Net Worth 1,657,187 1,602,726 1,507,246 1,432,208 1,338,592 1,292,258 1,254,479 20.37%
NOSH 9,440,107 9,433,790 9,432,874 9,430,754 9,427,009 9,426,499 6,283,180 31.14%
Ratio Analysis
30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 CAGR
NP Margin 12.58% 12.34% 12.12% 11.87% 12.10% 12.46% 11.96% -
ROE 32.47% 32.15% 33.19% 33.02% 35.22% 35.64% 32.49% -
Per Share
30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 CAGR
RPS 45.33 44.29 43.76 42.27 41.32 39.23 54.26 -11.28%
EPS 5.70 5.46 5.30 5.02 5.00 4.89 6.49 -8.28%
DPS 2.80 2.50 2.30 2.17 2.17 2.10 2.85 -1.17%
NAPS 0.1756 0.1699 0.1598 0.1519 0.142 0.1371 0.1997 -8.20%
Adjusted Per Share Value based on latest NOSH - 9,430,754
30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 CAGR
RPS 45.23 44.17 43.63 42.14 41.18 39.09 36.03 16.35%
EPS 5.69 5.45 5.29 5.00 4.98 4.87 4.31 20.32%
DPS 2.79 2.49 2.29 2.16 2.16 2.09 1.89 29.61%
NAPS 0.1752 0.1694 0.1593 0.1514 0.1415 0.1366 0.1326 20.38%
Price Multiplier on Financial Quarter End Date
30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 CAGR
Date 29/09/23 30/06/23 31/03/23 30/12/22 30/09/22 30/06/22 31/03/22 -
Price 1.51 1.59 1.55 2.00 1.97 2.07 3.46 -
P/RPS 3.33 3.59 3.54 4.73 4.77 5.28 6.38 -35.14%
P/EPS 26.48 29.10 29.23 39.87 39.39 42.36 53.33 -37.26%
EY 3.78 3.44 3.42 2.51 2.54 2.36 1.88 59.23%
DY 1.85 1.57 1.48 1.08 1.10 1.01 0.82 71.93%
P/NAPS 8.60 9.36 9.70 13.17 13.87 15.10 17.33 -37.29%
Price Multiplier on Announcement Date
30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 CAGR
Date 20/11/23 09/08/23 11/05/23 14/02/23 08/11/22 04/08/22 13/05/22 -
Price 1.61 1.43 1.59 1.75 1.98 2.32 3.55 -
P/RPS 3.55 3.23 3.63 4.14 4.79 5.91 6.54 -33.43%
P/EPS 28.24 26.18 29.98 34.89 39.59 47.48 54.72 -35.63%
EY 3.54 3.82 3.34 2.87 2.53 2.11 1.83 55.18%
DY 1.74 1.75 1.45 1.24 1.09 0.90 0.80 67.79%
P/NAPS 9.17 8.42 9.95 11.52 13.94 16.92 17.78 -35.66%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment